ABCDX: Heart-type fatty acid binding protein as biomarker for Transient Ischemic Attack

The study, conducted by an esteemed team of researchers including Daisy Guamán-Pilco, Elvira Chocano, Elena Palà, Marcel Lamana-Vallverde, Anna Penalba, Paula García-Rodríguez, Marta Rubiera, Alejandro Bustamante, Alex Rovira, Soledad Pérez-Sánchez, Leire Azurmendi-Gil, Sandrine Reymond, Jean-Charles Sanchez, and Joan Montaner, explores the potential of Heart-type fatty acid binding protein in differentiating Transient Ischemic Attack from its mimics. The findings, derived from data involving 175 patients, demonstrated that Heart-type fatty acid binding protein levels were significantly higher in individuals with Transient Ischemic Attack compared to those with mimic conditions, showcasing the biomarker's discriminative power.

ABCDx has harnessed this groundbreaking research to develop VasCheck, a rapid test utilizing Heart-type fatty acid binding protein, designed for point-of-care testing. The VasCheck system, complemented by the VasCheck reader, allows for quick and reliable measurement of Heart-type fatty acid binding protein levels, facilitating early and accurate diagnosis of Transient Ischemic Attack in emergency and primary care settings.

Joan Montaner, co-author of the study and Chief Medical Officer at ABCDx, stated, "The acceptance of our study underscores the importance of Heart-type fatty acid binding protein as a promising biomarker for Transient Ischemic Attack. The rapid application of point-of-care tests for Heart-type fatty acid binding protein measurement, as demonstrated by our VasCheck test, supports its potential use in real-world clinical settings, providing a significant advantage in the early diagnosis and treatment of Transient Ischemic Attack."